Skip to main content
. 2022 May 14;2022:baac030. doi: 10.1093/database/baac030

Figure 3.

Figure 3.

A case study on BRCA1 in breast cancer. Using ‘Search SL by disease’, the SL genes associated with the disease will be shown. BRCA1 is a gene that has SL partners and is downregulated in breast cancer. Click the ‘Search SL’ button, and it shows that PARP2 is an SL partner of BRCA1 with a high confidence score (0.87). Inspecting this pair of SL genes, we notice that BRCA1 and PARP2 are both associated with the ‘ovarian cancer’ and ‘breast cancer’ diseases, and BRCA1 participates in the ‘DNA Damage Response’ pathway. The infobox at the upper right corner shows the annotations of the SL. The synthetic lethal relationship between BRCA1 and PARP2 has been reported in the literature on human cancer and cell lines including A549, PC3 and MDA468. The result that breast cancer downregulates BRCA1 and PARP2 is an SL partner of BRCA1 indicates that PARP2 is a drug target for breast cancer. Rucaparib, Talazoparib, Niraparib and Olaparib all bind with PARP2. Using ‘Search SL by compound’, we also identify PARP2 as a potential drug target of Rucaparib, Talazoparib, Niraparib and Olaparib.